Abstract 4373112: High-dose Aspirin is more effective than Low-dose Aspirin for Prevention of Preeclampsia in High-risk Pregnant Women: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

M Mohammed Sabri Hassanin (Faculty of Medicine, Al-azhar university, Cairo, Egypt) A Abdulrahman Qenawy (Faculty of Medicine, South Valley University, Qena, Egypt) A Ahmed Wahdan Kasem (Faculty of Medicine, Al-azhar university, Cairo, Egypt) Y Yasein F. Awadalla (Faculty of Science, Al-Azhar University, Cairo, Egypt) R Raghad Aljanadi (Faculty of Medicine, Al-Azhar University, Cairo, Egypt) R Rawan Mohammed Awad (Collage of Pharmacy, King Saud University (KSU), Riyadh, Saudi Arabia) M Mohammed Yousef Awad (Faculty of Medicine, Mansoura University, Mansoura, Egypt) A Abdullah Nasser Ghonim (Faculty of Medicine, Al-Azhar University, Cairo, Egypt) M Mahmoud Hussein S Sultan Bander AlSulaiman (College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia) F Fahad Mohsin Alotaibi (College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia) M Mazen Ibrahem Gado (Faculty of Medicine, Mansoura University, Mansoura, Egypt) E Elsayed Balbaa (Alexandria University, Alexandria, Egypt) A Ahmed Sobhy A Abdelrahman Hafez (Cardiology Department, Mayo Clinic, Phoenix, Arizona, United States)

Abstract

Introduction: Preeclampsia is a multisystem progressive disease of pregnancy, characterized by a new onset of hypertension (≥ 140/90 mm Hg) with proteinuria after the 20th week of gestation. There is a conflict between United States guidelines that recommend Low-dose aspirin (LDA) and United Kingdom guidelines that recommend High-dose aspirin (HDA) for the prevention of preeclampsia in high-risk pregnant women. After the latest study that recommends HDA and the absence of pairwise meta-analyses comparing two doses, we aimed to conduct a comprehensive pairwise meta-analysis to assess whether HDA is better than LDA in the prevention of preeclampsia. Methods: We conducted a systematic search on PubMed, Scopus, Cochrane Central, and Web of Science (WOS) from inception until June 2025. All randomized controlled trials (RCTs) comparing LDA and HDA in high-risk pregnant women were included. Our primary outcome was the incidence of preeclampsia (PE), while secondary outcomes were Placental abruption, Pre-term delivery, and Intrauterine Growth Restriction (IUGR). Using random-effects models, we calculated risk ratios (RR) with 95% confidence intervals (CIs). Results: A total of 8 RCTs with 1,290 patients from the United States, Canada, England, and different Asian countries were included, among whom 642 (49.8%) patients were randomized to HDA. All studies compared HDA (≥ 150 mg) and LDA (75 mg to 81 mg). Patients with LDA had a higher risk of Preeclampsia (RR: 1.71, 95% CI: 1.19 to 2.44, p<0.001) compared to HDA. There was no significant difference between the LDA and HDA regarding Placental abruption, Pre-term delivery, and IUGR. With a pooled RR with a 95% CI (1.8, [0.91 to 3.54], P = 0.09), (1.25, [0.79 to 1.97], P = 0.34), (1.5, [0.93 to 2.42], P = 0.1), respectively. Conclusion: Among high-risk pregnant women, LDA was associated with a 71% higher incidence of preeclampsia than HDA. These results support the use of HDA as a preventive medication for preeclampsia in high-risk pregnant women.

Article Details

Journal Circulation
Volume / Issue Vol. 152, Issue Suppl_3
Published November 04, 2025
ISSN 0009-7322
Publisher Lippincott Williams & Wilkins

Journal Info

Circulation

Lippincott Williams & Wilkins

ISSN: 0009-7322 Health Sciences

Authors (15)

M

Mohammed Sabri Hassanin

Faculty of Medicine, Al-azhar university, Cairo, Egypt

A

Abdulrahman Qenawy

Faculty of Medicine, South Valley University, Qena, Egypt

A

Ahmed Wahdan Kasem

Faculty of Medicine, Al-azhar university, Cairo, Egypt

Y

Yasein F. Awadalla

Faculty of Science, Al-Azhar University, Cairo, Egypt

R

Raghad Aljanadi

Faculty of Medicine, Al-Azhar University, Cairo, Egypt

R

Rawan Mohammed Awad

Collage of Pharmacy, King Saud University (KSU), Riyadh, Saudi Arabia

M

Mohammed Yousef Awad

Faculty of Medicine, Mansoura University, Mansoura, Egypt

A

Abdullah Nasser Ghonim

Faculty of Medicine, Al-Azhar University, Cairo, Egypt

M

Mahmoud Hussein

S

Sultan Bander AlSulaiman

College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia

F

Fahad Mohsin Alotaibi

College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia

M

Mazen Ibrahem Gado

Faculty of Medicine, Mansoura University, Mansoura, Egypt

E

Elsayed Balbaa

Alexandria University, Alexandria, Egypt

A

Ahmed Sobhy

A

Abdelrahman Hafez

Cardiology Department, Mayo Clinic, Phoenix, Arizona, United States